

Biomarkers of Coronary Microvascular Dysfunction in Patients With Microvascular Angina: A Narrative Review

Angiology
2022, Vol. 73(5) 395–406
© The Author(s) 2021
Article reuse guidelines:
sagepub.com/journals-permissions
DOI: 10.1177/00033197211034267
journals.sagepub.com/home/ang


Vincenzo Sucato, MD^{1,2}, Egle Corrado, MD^{1,2}, Girolamo Manno, MD^{1,2} ,
Francesco Amata, MD², Gabriella Testa, MD^{1,2}, Giuseppina Novo, MD^{1,2},
and Alfredo R Galassi, MD²

Abstract

The current gold standard for diagnosis of coronary microvascular dysfunction (CMD) in the absence of myocardial diseases, whose clinical manifestation is microvascular angina (MVA), is reactivity testing using adenosine or acetylcholine during coronary angiography. This invasive test can be difficult to perform, expensive, and harmful. The identification of easily obtainable blood biomarkers which reflect the pathophysiology of CMD, characterized by high reliability, precision, accuracy, and accessibility may reduce risks and costs related to invasive procedures and even facilitate the screening and diagnosis of CMD. In this review, we summarized the results of several studies that have investigated the possible relationships between blood biomarkers involved with CMD and MVA. More specifically, we have divided the analyzed biomarkers into 3 different groups, according to the main mechanisms underlying CMD: biomarkers of “endothelial dysfunction,” “vascular inflammation,” and “oxidative stress.” Finally, in the last section of the review, we consider mixed mechanisms and biomarkers which are not included in the 3 major categories mentioned above, but could be involved in the pathogenesis of CMD.

Keywords

coronary microvascular dysfunction, microvascular angina, endothelial dysfunction, inflammation, oxidative stress, biomarkers

Introduction

Microvascular angina (MVA), first described by Kemp in 1973 with the term “Cardiac Syndrome X,” is characterized by (a) symptoms of myocardial ischemia: effort and/or rest angina or angina equivalents (i.e., shortness of breath), (b) absence of significant flow-limiting obstructive coronary artery disease (CAD) (< 50% diameter reduction) on invasive coronary angiography and/or computed tomography angiography, (c) evidence of ischemia assessed with non-invasive methods, and (d) evidence of impaired coronary microvascular function.^{1,2} Risk factors most frequently associated with this disorder are aging, hypertension, diabetes, metabolic syndrome, obesity, inflammation, and female sex.³ Figure 1 resumes main clinical manifestations of MVA.

It has been proposed that the onset of angina in patients with non-obstructive CAD might be caused by non-ischemic mechanisms, such as neurogenic and behavioral disorders, which cause an increased adrenergic activity and/or abnormal function of sympathetic and nociceptive nerve fibers of the heart, leading to an enhanced pain perception to harmless local stimuli.^{4,5} It is also possible that estrogen deficiency in women with MVA contributes to altered chest pain perception.⁶

However, the main mechanism which leads to myocardial ischemia in patients with MVA is coronary microvascular dysfunction (CMD), defined as alterations involving the structure or vasoreactivity of the coronary microcirculation.⁷ See Figure 2.

The microcirculation consists of very small vessels that cannot be visualized by coronary angiography, such as extra-myocardial pre-arterioles (300–150 µm), arterioles (150–10 µm), capillaries (8–4 µm), and venules (10–100 µm).⁸ These small vessels account for 70% of coronary resistance and are therefore major determinants of coronary blood flow regulation.⁸ Structural alterations of the coronary microcirculation may include

¹Unit of Cardiology, University Hospital Paolo Giaccone, University of Palermo, Palermo, Italy

²Department of Excellence of Sciences for Health Promotion and Maternal-Child Care, Internal Medicine and Specialties (ProMISE), University of Palermo, Palermo, Italy

Corresponding Author:

Girolamo Manno, Unit of Cardiology, Department of PROMISE, University Hospital Paolo Giaccone, University of Palermo, Via del Vespro 147, Palermo 90127, Italy.

Email: girolamomanno@hotmail.it




Figure 1. Main clinical manifestations of microvascular angina.




Figure 2. Close correlation of main microvascular dysfunction mechanisms.

vascular wall remodeling, microvascular atherosclerosis, and capillary rarefaction.⁹ Functional alterations may include a reduction of the vasodilator response and an increased vasoconstrictor activity, that is, microvascular spasm, mainly due to endothelial and smooth muscle cells dysfunction.¹⁰

CMD is linked not only to traditional cardiovascular risk factors such as hypertension, smoking, hyperlipidemia, and diabetes, but also to several atherogenic factors such as inflammation, oxidative stress, and thrombosis.¹¹⁻¹⁴ Assessment of coronary microvascular function can be carried out using invasive and non-invasive methods; in particular, it can be

documented by the evidence of one of the following: (a) in the absence of critical stenosis of epicardial vessels, a *coronary flow reserve* (CFR) ≤ 2.0 , defined as the ratio between coronary blood flow (CBF) at peak drug administration (usually adenosine) and at baseline.² The evaluation of CFR helps to investigate the intrinsic dilator capacity of the coronary microcirculation; (b) *coronary microvascular spasm*, defined as the onset of ischemic symptoms and ECG ischemic changes, without epicardial spasm, during acetylcholine testing; (c) *abnormal coronary microvascular resistance indices* (IMR > 25 , a more specific measurement of microvascular function); and (d) *coronary slow flow phenomenon*, defined as thrombolysis in myocardial infarction (TIMI) frame count > 25 , a marker of coronary vascular resistance that reflects the severity of CMD.

We aim to provide a narrative review of the literature in the last 20 years. We used PubMed to find studies that have investigated the possible diagnostic and prognostic potential of several biomarkers involved in different pathways related to CMD and MVA. These markers may allow to better understand the pathophysiological mechanisms that underlie these conditions. The keywords we used to search on PubMed were endothelial dysfunction, coronary microvascular dysfunction, oxidative stress, microvascular angina, and biomarkers.

From a pathophysiological point of view, CMD and MVA are intriguing conditions because they are caused by several closely related factors, which form the basis of the structural and functional alterations of the microvascular system. The main mechanisms and related biomarkers are analyzed individually below.

Biomarkers of Endothelial Dysfunction

The vascular endothelium regulates blood vessel function, contributing to the maintenance of their homeostasis.¹⁵ Many factors can directly interact with the endothelium, such as vascular inflammation, activated platelets, coagulation factors, and circulating cells, and in some cases, they can impair its function.¹⁶ Endothelial dysfunction is not only considered as the initial mechanism that occurs in the cascade of events that will lead to atherosclerosis and the development of CAD, but it also plays a pathogenic role in MVA.^{17,18} Several studies have investigated the role of different biomarkers related to endothelial dysfunction in patients with MVA. We consider the main ones below.

Endothelins

Endothelial dysfunction is a key mediator in the pathogenesis of CMD. This has been shown in experimental studies, where the attenuation of endothelium-dependent vasodilation results from reduced nitric oxide bioavailability and increased vasoconstrictor responses to endothelin-1 (ET-1), prostaglandin H₂, and thromboxane A₂.¹⁹

The endothelins (ETs) are a family of endothelial peptides with a strong vasoconstrictor and neuromodulator effect,

released as a consequence of endothelial stimulation and activation by several stimuli, which sometimes can be harmful to the endothelium. Indeed, increased plasma ET levels are found in acute coronary syndrome, atherosclerosis, hypertension, and renal failure.²⁰⁻²³ ETs exert their vasoconstrictor effect mainly on the microcirculation and are also able to stimulate nociceptors; thus these peptides may play a role in the pathophysiology of MVA.²⁴ Indeed, experimental studies have shown that structural inward remodeling of arterioles can be produced at low intraluminal pressure in vitro and is enhanced by ET-1 and prevented by the calcium-antagonist amlodipine.^{13,19}

Kaski et al.²⁵ found that in 40 patients with MVA who underwent treadmill exercise testing and SPECT (single-photon emission computed tomography) coronary perfusion assessment, plasma ET-1 levels were significantly higher than those in 20 healthy controls. Moreover, in patients with "high" ET-1 concentrations (n = 23), levels were positively correlated with an earlier onset of chest pain during treadmill stress testing. In another study, plasma ET levels were assessed in 54 patients with MVA.²⁶

MVA patients were subdivided into 4 subgroups according to the presence of a left bundle branch block (group A), history of previous myocardial infarction (group B), positive ECG response to exercise stress testing (group C), and negative ECG response to exercise stress testing (group D) compared with a group of healthy controls (E). Only subgroups A, B, and C had significantly higher ET levels than the group of healthy controls; in particular, the highest levels were found in subgroups A and B. Cox et al.²⁷ enrolled 19 patients with chest pain and normal coronary arteriograms who underwent radioimmunoassay measurement of arterial and coronary sinus ET levels and invasive assessment of coronary sinus blood flow during rapid atrial pacing. They found that the percentage fall in coronary vascular resistance (d.CVR%) was higher in female patients than in males; in particular, women with high arterial ET levels had lower levels of coronary vascular resistance (d.CVR%). Further investigations would be helpful to understand whether treatment with endothelin antagonists could improve endothelial function in these patients.

Platelets. Platelets play a role in the pathogenesis of microvascular dysfunction by forming distal microemboli and by adhering to the endothelium or to attached leucocytes, contributing to the release of vasoconstrictor or toxic molecules and turning platelets into boosters of the inflammatory process.^{16,28} Oxidative stress reduces NO levels and increases ET-1 expressions in the endothelial cells, enhancing vasoconstriction, proliferation of fibroblasts and vascular smooth muscle cells, triggering inflammatory pathways and platelets adhesion.^{18,29} Indeed, oxidative stress, endothelial cell activation, and the recruitment of rolling leucocytes contribute to the interaction with intact inflamed microvessels without the need of exposed extracellular matrix material.²⁸ Molecules mediating this interaction are P-selectin and P-selectin

glycoprotein ligand-1 or glycoprotein-Ib and the von Willebrand factor.²⁹ Proteins from preformed granules, synthesized bioactive molecules (ROS and thromboxane) such as chemokines, TNF superfamily factors and coagulation factors, or shed from the membrane (e.g., CD40L) are released from platelets in the endothelial cell lining.²⁸ In this way, platelets provide leucocytes/monocytes recruitment and activation-promoting inflammation.

Endocan. Endocan is a soluble dermatan sulfate proteoglycan produced by the endothelium as a result of its activation and dysfunction. This molecule seems to participate in the regulation of the cell adhesion process, inflammation, tumor progression, angiogenic switch in stem cells, and endothelial-mesenchymal transition processes.³⁰⁻³² Endocan may be a predictor of cardiovascular disease events,³³ and its plasma levels are associated with the presence and severity of CAD in hypertensives.^{34,35} Çimen et al.³⁶ measured plasma endocan levels in 40 MVA patients, 120 obstructive CAD patients, and 53 healthy controls. They found that CAD and MVA patients had similar endocan levels that were higher than those of controls. Furthermore, plasma endocan levels were independent predictors of the presence and severity of CAD in both hypertensive and normotensive patients. Efe et al.³⁷ also found higher plasma endocan levels in 50 patients with MVA compared to 28 healthy controls. A diagnosis of MVA was based on typical exercise-induced angina, positive exercise stress electrocardiography (ECG; > .1 mV ST-segment depression at 80 ms after the J point in 2 or more contiguous leads), or myocardial perfusion scintigraphy (MPS), and angiographically normal coronary arteries.

In particular, in receiver operating characteristic (ROC) curve analysis, plasma endocan levels > 2072 ng/l had 72% sensitivity and 54% specificity to predict a diagnosis of MVA.

Endocan may be considered as a surrogate indicator of early endothelial dysfunction; therefore it might be a hypothetical therapeutic target for the primary prevention of cardiovascular diseases. Endocan might be a marker of microvascular disease and is an indicator of pathophysiology of MVA.

- However further studies are needed to confirm that endocan could be a common predictor of the endothelium-dependent inflammatory processes.

Angiogenic Factors

Angiogenic factors, such as vascular endothelial growth factor (VEGF), tyrosine kinase-2 receptor (Tie-2), and its ligands; angiopoietin-1 (Angp-1); and angiopoietin-2 (Angp-2) are important proteins which regulate the processes of vascular development and angiogenesis.³⁸ In patients with cardiovascular diseases, such as congestive heart failure and acute coronary syndrome, higher levels of Angp-1, Angp-2, and Tie-2 have been reported.^{39,40} Moreover, angiogenic factors

have been investigated for their possible role in affecting endothelial function and integrity, leading to CMD and MVA. Asl et al.⁴¹ measured angiogenic factors levels in 30 MVA patients and 20 healthy controls; they found that the patients had significantly higher levels of Angp-2 and Tie-2 than controls. Afterward, patients with MVA underwent 4 weeks of metoprolol therapy, and at the end of this period, no significant changes were found in the levels of angiogenic factors compared with baseline values.

Changes in plasma levels of angiogenic factors in patients with MVA require further investigations in order to better understand their role in the pathogenesis of MVA and possibly implement targeted treatment.

Biomarkers of Vascular Inflammation

Systemic inflammation has a pathogenic role in endothelial dysfunction and atherogenesis.^{42,43} Several inflammatory markers have been investigated for their possible pivotal role leading to CMD.

C-Reactive Protein

C-Reactive Protein, a sensitive nonspecific marker of systemic inflammation, is a cardiovascular risk predictor associated with endothelial dysfunction and atherogenesis.⁴²⁻⁴⁵ Thus, its possible role in MVA has been investigated.

Arroyo-Espliguero et al.⁴⁶ studied for the first time the association between chronic inflammation and increased arterial stiffness in 30 patients with MVA compared with 30 healthy controls by evaluating high sensitivity CRP (hsCRP) levels and ultrasound parameters of arterial elasticity. Cosin-Sales et al.⁴⁷ measured plasma hsCRP levels in 137 patients with typical chest pain and angiographically normal coronary arteries who completed a standardized angina and cardiovascular risk factor questionnaire, and underwent treadmill exercise stress testing and 24-h continuous ambulatory ECG monitoring (Holter). They found that hsCRP levels were higher in patients with prolonged (> 20 min) and frequent (> 5/week) angina episodes, with a positive exercise stress testing and with ST-segment changes during 24-h Holter monitoring. In addition, they also noticed a direct correlation between hsCRP levels and the severity of ischemic responses on stress testing and with the number of ST-segment changes during 24-h Holter monitoring. Recio-Mayoral et al.⁴⁸ measured plasma hsCRP levels in 21 patients with MVA without traditional cardiovascular risk factors and 21 healthy volunteers who underwent PET (positron emission tomography) assessment of myocardial blood flow and CFR (coronary flow reserve). Patients were subdivided into 2 groups according to hsCRP levels (≤ 3 or > 3 mg/L). MVA patients had lower CFR values compared with controls; moreover, patients with hsCRP > 3 mg/L had a greater impairment of CFR and more frequent ischemic ECG changes during adenosine infusion. As a result, the correlation was reported between

inflammation, CMD, and the occurrence of ischemic episodes, even in the absence of conventional cardiovascular risk factors.

Cell Adhesion Molecules

Cell adhesion molecules, such as ICAM-1 and VCAM-1, are trans-membrane proteins that allow blood circulating cells to adhere to other cells or to the extracellular matrix. VCAM-1 (vascular cell adhesion molecule-1) and ICAM-1 (intercellular cell adhesion molecule 1) are expressed by the endothelium as it becomes inflamed and activated by cytokine stimuli and promote the adhesion of circulating leukocytes on endothelial cells, their migration, and atherosclerosis.⁴⁹ Tousoulis et al.⁵⁰ measured circulating VCAM-1 and ICAM-1 levels in 36 patients with CAD, 21 patients with MVA, and 11 healthy volunteers. CAD and MVA patients showed higher levels of these molecules compared with controls, although only the differences in ICAM-1 levels were significant ($P < .05$). Moreover, in patients with MVA there was no significant evidence of correlation between circulating cell adhesion molecules levels and the magnitude of ST-segment depression. Shim et al.⁵¹ found that in 135 patients with MVA, among several inflammatory biomarkers of early coronary atherosclerosis measured, such as soluble vascular cell adhesion molecule (sVCAM-1), interleukin 6 (IL-6), monocyte chemoattractant protein-1 (MCP-1), and lipoprotein-phospholipaseA2 (Lp-PLA2), only plasma sVCAM-1 levels influenced the CFR, as demonstrated by the evidence of an inverse correlation between these 2 parameters. In particular, sVCAM-1 levels were significantly higher in patients with CFR < 2.0 , leading to the idea that because sVCAM-1 is expressed in subclinical atherosclerosis and endothelial activation, patients with MVA might also manifest higher levels of this biomarker. Liang et al.⁵² compared serum levels of hsCRP, ICAM-1, VCAM-1, MCP-1, and soluble CD40 ligand (sCD40L) in 92 MVA patients and 145 CAD patients without known diabetes, finding that the CAD group had higher levels of VCAM-1 and ICAM-1 compared with the MVA group. Moreover, they found that VCAM-1 levels might be a predictor of the differential diagnosis of CAD vs MVA.⁵²

Inflammatory Cytokines

Cytokines are small proteins produced by a variety of cells (i.e., mononuclear cells, activated T-cells, platelets, endothelial cells, and smooth muscle cells) in response to several stimuli; they can act as signals that allow the communication between the immune cells and between these cells and different organs and tissues.⁵³ Cytokines can be involved in several inflammatory pathways and can also have pro-atherogenic effects, affecting endothelial function and increasing leukocyte recruitment.⁵³ Therefore, they may also be involved in the pathogenesis of CMD and MVA.

MCP-1 was one of the first inflammatory cytokines evaluated in the possible association with CMD, as it stimulates monocytes to infiltrate the arterial wall in early atherogenesis.⁵⁴ Deo et al.⁵⁵ were the first to evaluate the correlation between high serum MCP-1 levels with subclinical atherosclerosis and traditional cardiovascular risk factors. On et al.⁵⁶ assessed the total serum antioxidant status, plasma CRP levels, and inflammatory cytokines (P-selectin, MCP-1, IL-6, IL-10) in 36 patients with MVA, 36 patients with CAD, and 24 controls who had experienced atypical chest discomfort with normal coronary angiograms and without the evidence of ischemic episodes in non-invasive tests. Patients with MVA had higher CRP levels compared with the other groups, whereas controls had higher total serum antioxidant status levels but lower serum MCP-1 concentration. Blood levels of the other cytokines were similar in the entire population of the study. Li et al.⁵⁷ measured plasma CRP and IL-6 levels and circulating leukocytes in 36 female patients with MVA and 30 female healthy controls. Patients with MVA had significantly higher peripheral circulating leukocytes and monocytes counts, and 2.2-fold higher CRP and IL-6 levels compared with controls. Moreover, CRP was independently associated with MVA. Other cytokines studied were suppression of tumorigenicity 2 (sST2) and sCD40L, which are involved in inflammation and fibrosis. Aslan et al.⁵⁸ evaluated serum sST2 and sCD40L levels in a population of 91 patients with MVA and 61 controls with story of chest pain but with normal coronary angiograms and absence of ischemic evidence on non-invasive tests. Serum sST2 and sCD40L levels were significantly higher in patients with MVA compared with controls; there was also a significant positive correlation between sST2 levels with low-density lipoprotein-cholesterol (LDL-C) and sCD40L. Moreover, sCD40L levels were also positively correlated with hsCRP levels. Finally, only sCD40L and hsCRP levels were found to be independently associated with MVA. In order to better understand the internal relationships between different biomarkers involved in common pathophysiological pathways that possibly can lead to CMD, Schroder et al.⁵⁹ measured a panel of 92 biomarkers related to cardiovascular or other diseases in 174 women with anginal-like symptoms and no significant obstructive CAD, who underwent transthoracic doppler echocardiography to measure their coronary flow velocity reserve (CFVR). Only 28% of patients had a CFVR < 2.0, which was indicative of CMD. On a regression analysis, 18 biomarkers were significantly related to CFVR; by using the statistical technique PCA (principal component analysis), which allowed a simplification of the large number of variables analyzed in order to explore possible common interrelations within the group of biomarkers significantly associated with CFVR, it was found that 8 biomarkers such as chemokine ligand 16 (CCL16), C-X-C motif chemokine ligand 16 (CXCL16), growth differentiation factor-15 (GDF15), peptidoglycan recognition proteins (PGLYRP1), suppression of tumorigenicity-2 (ST2), tumor necrosis factor receptor-1 (TNFR1), soluble urokinase-type plasminogen

activator receptor (suPAR), and TNF receptor superfamily member 10c (TNFRSF10C) were interrelated and most of them were involved in TNF- α and IL-6 pro-inflammatory pathways.

Monocyte to High Density Lipoprotein-Cholesterol (HDL-C) Ratio (MHR)

The MHR is considered a predictor of major cardiovascular events.^{60,61} Monocytes represent the majority of the inflammatory cells infiltrating the arterial wall in early atherogenesis and are involved in the release of pro-inflammatory and pro-oxidative cytokines at sites of inflammation; thus, they play an important role in chronic inflammation and cardiovascular diseases. HDL-C has anti-inflammatory and antioxidant effects, preventing the migration of macrophages, removing cholesterol molecules from these cells, and inhibiting monocyte production and mobilization. Dogan et al.⁶² found that the MHR can be used in clinical practice as an easy detectable marker of inflammation in the diagnosis of MVA patients. Indeed, comparing the MHR in 105 patients with MVA and 125 healthy controls, the patients had significantly higher values of this ratio than controls, due to an increased monocyte count and decreased HDL-C levels.

Pentraxin-3

Pentraxin-3 is a marker of systemic inflammation structurally and functionally similar to CRP, produced by a variety of inflammatory cells.⁶³ It is a marker of vascular inflammation associated with increased cardiovascular risk.⁶⁴ Büyükkaya et al.⁶⁵ measured serum PTX-3 and hsCRP levels in 41 MVA patients, 41 stable CAD patients, and 40 controls with angina symptoms without evidence of myocardial ischemia. MVA and CAD patients had higher PTX-3 and hsCRP levels than controls; however, no differences were observed between MVA and CAD groups. Serum PTX-3 and hsCRP levels were positively correlated.

Soluble Urokinase-Type Plasminogen Activator Receptor. The soluble urokinase-type plasminogen activator receptor is a biomarker with pro-inflammatory and chemotactic effects which promote immune activation and fibrinolysis inhibition. This molecule is released by cleavage of uPAR, which is expressed on the membrane of hematopoietic, endothelial, and smooth muscle cells.⁶⁶ Unlike CRP, suPAR is a very stable biomarker which is not subject to circadian variations.⁶⁶ Plasma suPAR levels have been shown to predict cardiovascular outcomes independently of CRP or traditional risk factors. Indeed, elevated systemic plasma suPAR levels have been associated with increased risk of major adverse cardiovascular outcomes in advanced CAD.^{67,68}

Mekonnen et al.⁶⁹ measured plasma suPAR levels in 66 patients with an abnormal non-invasive stress test, stable angina, or stabilized acute coronary syndrome, but without

angiographic evidence of CAD. They demonstrated for the first time that plasma suPAR levels were associated with CMD: indeed, suPAR correlated negatively with CFR and, after adjustment for cardiovascular risk factors and hsCRP levels, it remained an independent predictor of CFR impairment. Corban et al.⁷⁰ hypothesized that local production of suPAR and plasminogen activator inhibitor-1 (PAI-1) is associated with coronary endothelial dysfunction; thus, they measured left main and coronary sinus suPAR and PAI-1 levels, as well as cross-coronary suPAR and PAI-1 production rates, in 79 patients with angina who had angiographically normal coronary arteries or mild epicardial CAD (< 40% stenosis). All patients underwent acetylcholine coronary vasomotor testing to assess the presence of epicardial endothelial dysfunction (EED, defined as a decrease in coronary artery diameter > 20% after acetylcholine) and microvascular endothelial dysfunction (MED, defined as a change < 50% in coronary blood flow after acetylcholine infusion). Patients with MED had significantly higher local median coronary suPAR production compared with all other patients. Conversely, patients with EED had significantly higher median local coronary PAI-1 production compared with those with normal epicardial endothelial function. This is the first study to link local coronary suPAR production to endothelial dysfunction at the microvascular level.

Heat Shock Proteins

Heat shock proteins are a family of intracellular chaperone proteins with cytoprotective functions essential for cell survival in both physiological and stress conditions. The increased production of these proteins following stressful events can lead to the activation of the immune system with the onset of an inflammatory reaction.⁷¹ Hsp60 and Hsp72 have been linked to the atherosclerotic process and to ischemic myocardial damage.^{72,73} Hsp60, produced by endothelial cells and myocytes in response to biochemical and/or infective insults, seems to participate in inflammatory processes leading to early atherogenesis.⁷¹ Hsp72 is involved in the “hibernation” of myocytes, a myocardial adaptive process to chronic ischemia, with the role of myocardial cells’ protection.⁷²

Even if there are no studies that can specifically validate the role of Hsp as possible markers of CMD, Giannessi et al.⁷³ found a relationship between Hsp levels with the extent of myocardial and coronary microvascular damage. They enrolled 60 patients with idiopathic left ventricular dysfunction and angiographically normal coronary arteries (subdivided in 2 groups according to the severity of impairment of left ventricular ejection fraction (LVEF) and 22 healthy controls). There was a positive correlation between both the grade of left ventricle (LV) systolic dysfunction and the severity of CMD, assessed by rest/stress PET myocardial blood flow study, with plasma levels of Hsp60, Hsp72, anti-Hsp60 auto-antibody, CRP, and IL-6.

Biomarkers of Oxidative Stress

Increased oxidative stress occurs in case of an imbalance between antioxidant defenses and excessive pro-oxidant reactive molecules, and it plays an important role in inflammation, endothelial dysfunction, and atherogenesis.⁷⁴⁻⁷⁶ Oxidative stress seems to be involved in the pathophysiology of MVA by leading to an impaired endothelium-dependent vasodilatation of the coronary microvasculature and to the consequent decrease of CFR.^{77,78}

Superoxide Free Radicals and Mononuclear Cell Activity

Free radicals are highly reactive molecules that result from the increased oxidative stress and can impair cellular structure and function, causing cell death. The evaluation of the amount of superoxide free radicals in whole blood and the measurement of superoxide production by mononuclear cells during basal activity and after induced stimulation are valid methods to assess intravascular oxidative stress in patients with atherosclerosis or subclinical atherogenesis.^{79,80} In order to understand the possible role of mononuclear cell activity, endothelial inflammation, and oxidative stress in MVA, Lin et al.⁸¹ evaluated inflammatory biomarkers, plasma total nitrite/nitrate level, superoxide free radicals in whole blood, and mononuclear cell activity in 32 patients with MVA, 34 with CAD, and 17 healthy volunteers. MVA and CAD patients had different degrees of oxidative stress. In particular, only patients with MVA had significantly increased levels of superoxide free radicals in whole blood; conversely, only patients with CAD had an increased production of free radicals after the induced activation of monocytes. These results suggested that in MVA, there is no significant activation of circulating mononuclear cells, although there is evidence of an increased oxidative stress.

Nitric Oxide Synthetic Pathway, L-Arginine, and Asymmetric Dimethylarginine

Nitric oxide is a gaseous molecule with vasoactive action and vascular protective effects, which are mediated by the promotion of vasodilation, inhibition of platelets aggregation, adhesion of circulating leukocytes to the endothelium, and proliferation of smooth muscle cells. NO is produced by the action of the enzyme NO synthase (NOS), which converts L-arginine to NO and L-citrulline.^{82,83} ADMA is an endogenous methylarginine analogue of L-arginine which acts as an NOS competitive inhibitor, leading to a decrease in NO production and bioavailability. Other endogenous methylarginines, that is, symmetric dimethylarginine and monomethylarginine (MMA), inhibit the NO pathway.⁸⁴ L-arginine facilitates endothelium-dependent vasodilation, with protective effects on the endothelium; therefore, a reduced availability of L-arginine could be related to endothelial dysfunction.

Conversely, ADMA, which can be elevated in patients with hyperlipidemia, atherosclerosis, and hypertension, prevents NO-mediated vasodilatation with a role in endothelial dysfunction.^{85,86} NO in the vasculature is mainly produced by endothelial cells, though circulating cells are able to produce it as well. Indeed, red blood cells (RBCs) can produce NO, playing an important role in the regulation of systemic blood pressure.⁸⁷ Moreover, RBCs also express the enzyme arginase I, which regulates the function of NOS expressed in erythrocytes by competing with NOS for its common substrate arginine to form L-ornithine.⁸⁸ Oxidative stress can reduce NO bioavailability by interfering with NO metabolism, thus leading to impaired endothelium-dependent vasodilation and an increase in cardiovascular risk.⁸⁹ Consequently, these mechanisms can cause the onset of angina symptoms even in patients with normal coronary angiograms. Okay et al.⁹⁰ evaluated the correlations between plasma L-arginine and ADMA levels and their ratio with epicardial coronary blood flow, assessed by TIMI frame count method (TFC) and the grade of myocardial perfusion, valued by myocardial blush grade method (MBG). They enrolled 32 patients with MVA and 17 controls who complained of chest discomfort but with normal coronary angiograms and negative exercise stress testing. Both groups had similar L-arginine levels; however, MVA patients showed higher ADMA levels and lower L-arginine/ADMA ratio than controls. Moreover, ADMA levels were negatively correlated with MBG, whereas there was no evidence of correlations between TFC and other variables. Sen et al.⁹¹ studied possible correlations between plasma nitrate/nitrite (NOx), L-arginine, and ADMA levels with common carotid intima-media thickness (cIMT). The study population included 30 patients with MVA and 30 controls with angina pain, and normal coronary angiograms, and no evidence of ischemic episodes in non-invasive tests. MVA patients had a higher cIMT, number of carotid atherosclerotic plaques, and ADMA levels, but lower plasma NOx and L-arginine level compared with controls. cIMT was positively correlated with ADMA levels, but negatively with plasma NOx and L-arginine levels. In order to assess the degree of oxidative stress and the impairment of NO pathway of patients with MVA, Porro et al.⁹² measured the principal metabolites involved in Arg/NO metabolic pathway (in both plasma and lysed RBCs), oxidative stress, and RBC-NOS and arginase expression in a population of 25 patients with MVA, 22 patients with CAD, and 20 healthy controls. Oxidative stress was evaluated by the ratio between oxidized and reduced forms of glutathione. It was reported that MVA and CAD patients had similar inhibitor levels of the NO pathway (i.e., ADMA) in both plasma and RBCs, which were higher ($P < .05$ and $P < .001$, respectively) than those of controls. Conversely, controls had higher NOS expression in RBCs compared with patients. Finally, CAD patients had higher oxidative stress status and arginase I levels compared with other groups, even if oxidative stress of MVA patients was higher than in controls.

Further studies with larger cohorts are needed to better understand the clinical relevance of ADMA and L-arginine levels as prognostic factors that correlate with the severity of CMD.

Aminothiols

Aminothiols are biomolecules with a sulfhydryl group which have important antioxidant effects.⁹³ Among them, glutathione is located intracellularly, whereas cysteine is located extracellularly and can be present in an oxidized disulfide form, cystine, which is a surrogate marker for oxidative stress. Low glutathione levels or high cystine levels are associated with increased oxidative stress. Changes in plasma aminothiol levels are related to diabetes, impaired endothelial function, and atherosclerosis.⁹³ Moreover, a recent study found that disulfide/thiol homeostasis can be used as a novel parameter that reflects oxidative stress.⁹⁴ Dhawan et al.⁹⁵ investigated on the possible role of plasma aminothiol levels in CMD and in abnormal coronary arteries. In particular, they evaluated the association between CMD, epicardial plaque burden, plasma aminothiols, and inflammation in 47 patients undergoing cardiac catheterization. Lower plasma glutathione levels correlated with a greater plaque burden and plaque necrotic core content, as well as impaired microvascular function, expressed by lower CFVR and higher hyperemic microvascular resistance (HMR). Cystine was not related to any parameters, whereas higher cystine/glutathione ratio correlated to a lower CFVR and greater plaque necrotic core content.

Lipoprotein-cholesterol

Lipoprotein-cholesterol levels are important risk factors for the development of CAD. In particular, oxidized LDL, which are formed in the artery walls due to the oxidative effect of ROS (reactive oxygen species), stimulates chronic inflammation and epicardial coronary atherosclerosis.⁹⁶ Moreover, LDL-C levels inversely correlate with CFR in hypercholesterolemic subjects; therefore, these particles might play an important role in the impairment of coronary microcirculation.⁹⁷ Mangiacapra et al.⁹⁸ enrolled 95 patients with stable CAD who underwent coronary angiography and intracoronary functional evaluation. They found a significant positive correlation between total cholesterol and LDL-C with the index of microvascular resistance (IMR); in particular, LDL was an independent predictor of IMR.

Paraoxonase-I

Paraoxonase-1 is an enzyme associated with HDL-C which has 3 functions: PON, arylesterase, and dyazoxonase.⁹⁹ It seems to have anti-inflammatory and antioxidative effects by catabolizing highly reactive oxidized lipids in lipoproteins and cells. Hence, a decrease in PON-1 activity is associated with an increase in oxidative stress and atherosclerosis.¹⁰⁰ In line

with these data, Gur et al.¹⁰¹ enrolled 41 patients with MVA, 33 patients with atypical chest discomfort (but with normal coronary angiograms and without evidence of ischemic episodes in non-invasive tests), and 20 healthy controls. They found that serum PON-1 activity and total antioxidant status were significantly lower in the MVA group than in other groups; conversely, MVA patients had significantly higher lipid hydroperoxide levels. Moreover, serum arylesterase activity of PON-1 was negatively correlated to the grade of ST-segment depression in MVA group. Further studies are needed to better evaluate the possible diagnostic and prognostic importance of this enzyme in patients with CMD and MVA.

Lymphocyte DNA Damage

Lymphocyte DNA damage, which is mainly caused by oxidative stress and inflammation, is associated with atherosclerosis and increased levels of this marker were found in patients with CAD.^{102,103} Gur et al.¹⁰⁴ investigated, for the first time, the possible association between lymphocyte DNA damage and MVA in 23 patients with MVA, 21 patients with atypical chest discomfort, and 20 healthy controls. MVA patients showed higher lymphocyte DNA damage levels and lower total antioxidant status (TAS) levels, compared with other groups. Particularly, in patients with MVA, DNA damage levels had an independent correlation with TAS and hsCRP.

Mixed Mechanisms and Biomarkers

Several biomarkers, which are not included in the three major areas described above, could be involved and considered in mixed pathogenic mechanisms underlying MVA and CMD. Among these, we mention:

1. Plasminogen activator inhibitor type-1 (PAI-1): increased levels have been associated with endothelial dysfunction and inflammation in patients with MVA.¹⁰⁵
2. Adiponectin and lipoprotein(a) are associated with endothelial dysfunction, pro-thrombotic effects, and premature atherosclerosis.^{106,107}
3. Galectin-3: a member of the lectin family, has a possible role in the pathogenesis of microvascular dysfunction in terms of endothelial dysfunction, and pro-inflammatory and pro-fibrotic effects.¹⁰⁸
4. Endothelial progenitor cells (EPCs): EPC numbers are inversely correlated with risk factors for atherosclerosis, and reduced levels of EPCs are associated with endothelial dysfunction.¹⁰⁹
5. Hyperinsulinism and hyperglycemia are the main protagonists of MVA and correlate extensively with endothelial damage, neurohormonal dysfunction, and inflammation, as well as oxidative and wall stress.¹¹⁰⁻¹¹²

Table 1. Main Pathophysiological Mechanisms, Related Biomarkers, and References of CMD and MVA.

Pathophysiological Mechanisms	Biomarkers	References
Endothelial dysfunction	Endothelins	8, 12–19, 96–101
	Endocan	20–27
	Angiogenetic factors	7, 28–31
Vascular Inflammation	C-reactive protein	7,8, 32–38
	Cell adhesion molecules	7–9, 39–42
	Inflammatory cytokines	7–9, 43–47, 96–101
	Monocyte to HDL-C ratio	48–50
	Pentraxin-3	51–53
	SuPAR	54–58
Oxidative Stress	Superoxide free radicals	59–63
	Mononuclear cells activity	59–66
	Nitric oxide synthetic pathway,	7–9, 67–75
	L-arginine	67–75
	Asymmetric dimethylarginine	67–75, 96,97
	Aminothiols	76–78
Mixed Mechanisms	LDL-C	79–82, 96,97
	Lymphocyte DNA damage	83,84
	Plasminogen activator inhibitor type-I	86
	Adiponectin	87,88, 93,94
	Lipoprotein (a)	89
	Galectin-3	89
	Hyperinsulinism and hyperglycemia	91–95
	Neuropeptide Y	96,97

Abbreviations: CMD, microvascular dysfunction; HDL-C, high density lipoprotein-cholesterol; LDL-C, low density lipoprotein-cholesterol; MVA, microvascular angina; suPAR, soluble plasminogen activator urokinase receptor.

6. Neuropeptide Y (NPY): a peptide endogenous to human coronary arteries, which seems to cause constrictor effects on the coronary microcirculation. NPY can induce transient myocardial ischemia and can play a role in the genesis of angina in patients with MVA.^{15,113-116} Table 1 summarizes the main mechanisms, related biomarkers, and reference analyzed above.

Conclusion

CMD is the main mechanism which underlies MVA. Invasive methods, such as intracoronary Doppler wires or the intracoronary thermodilution-derived method, are considered the gold standard to measure the response to vasoactive stimuli of the coronary microcirculation; however, they can be difficult to perform, expensive, risky for the patient, and can also be associated with the prolongation of diagnostic angiography.¹¹⁷ In the absence of obstructive CAD, coronary microvascular dilator function can be investigated by several non-invasive

methods that allow measurement of the coronary blood flow, but some of them, that is, cardiac PET and cardiac RMN, cannot be used routinely in clinical practice due to their high cost and limited availability. Another non-invasive method is transthoracic Doppler echocardiography which is relatively inexpensive and more available, but it is operator dependent and sometimes, it is not possible to obtain good echocardiographic windows. Compared with these methods, the introduction in clinical practice of blood biomarkers detection in patients with suspected CMD and MVA can facilitate the diagnosis of these pathological conditions, offering several advantages, such as reduction of costs, less risk of physical harm, a greater availability/accessibility, and prognostic value.

As reported in this review, there are a variety of biomarkers involved in possible pathophysiological mechanisms responsible for the development of CMD and MVA; however, none of them has yet been validated for routine surveillance in this patient population and their management. In the near future, it is probable that the difficulties that at present prevent the introduction of blood biomarkers in the clinical routine will be overcome, following more evidence. Therefore, the use of biomarkers specific for CMD will be helpful in the differentiation between patients with epicardial CAD, CMD, and without any coronary flow abnormalities, as well as in the implementation of a specific target-therapy.

Author Contributions

All authors contributed as follows: (1) substantial contributions to conception and design, or acquisition of data, or analysis and interpretation of data, (2) drafting the article or revising it critically for important intellectual content, and (3) final approval of the version to be published.

Declaration of Conflicting Interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author(s) received no financial support for the research, authorship, and/or publication of this article.

ORCID iD

Girolamo Manno  <https://orcid.org/0000-0003-4588-6039>

References

1. Kemp HG. Left ventricular function in patients with the anginal syndrome and normal coronary arteriograms. *Am J Cardiol.* 1973;32:375-6.
2. Ong P, Camici PG, Beltrame JF, et al. International standardization of diagnostic criteria for microvascular angina. *Int J Cardiol.* 2018;250:16-20.
3. Sucato V, Novo G, Saladino A, Evola S, Galassi AR. Coronary microvascular dysfunction: an overview. *Minerva Cardioangiol.* 2020;68:153-63.

4. Lanza GA, Giordano A, Pristipino C, et al. Abnormal cardiac adrenergic nerve function in patients with syndrome X detected by [¹²³I] metaiodobenzylguanidine myocardial scintigraphy. *Circulation.* 1997;96:821-6.
5. Sucato V, Testa G, Puglisi S, Galassi AR, Novo G. Myocardial infarction with non-obstructive coronary arteries (MINOCA): intracoronary imaging-based diagnosis and management. *J Cardiol.* 2021;77:00004-6.
6. Kaski JC. Cardiac syndrome X in women: the role of oestrogen deficiency. *Heart.* 2006;92:5-9.
7. Camici PG, Crea F. Coronary microvascular dysfunction. *N Engl J Med.* 2007;356:830-40.
8. Vijayan S, Barnby DS, Pearson IR, Davies AG, Wheatcroft SB, Sivananthan M. Assessing coronary blood flow physiology in the cardiac catheterisation laboratory. *Curr Cardiol Rev.* 2017; 13:232-43.
9. Taqueti VR. Coronary microvascular dysfunction in vasospastic angina: provocative role for the microcirculation in macrovessel disease prognosis. *J Am Coll Cardiol.* 2019;74:2361-4.
10. Suda A, Takahashi J, Hao K, et al. Coronary functional abnormalities in patients with angina and nonobstructive coronary artery disease. *J Am Coll Cardiol.* 2019;74:2350-60.
11. Kinugawa S, Post H, Kaminski PM, et al. Coronary microvascular endothelial stunning after acute pressure overload in the conscious dog is caused by oxidant processes: the role of angiotensin II type 1 receptor and NAD(P)H oxidase. *Circulation.* 2003;108:2934-40.
12. Zhu Y, Carmeliet P, Fay WP. Plasminogen activator inhibitor-1 is a major determinant of arterial thrombolysis resistance. *Circulation.* 1999;99:3050-5.
13. Dayanikli F, Grambow D, Muzik O, Mosca L, Rubenfire M, Schwaiger M. Early detection of abnormal coronary flow reserve in asymptomatic men at high risk for coronary artery disease using positron emission tomography. *Circulation.* 1994; 90:808-17.
14. Mahmud A, Feely J. Arterial stiffness is related to systemic inflammation in essential hypertension. *Hypertension.* 2005;46: 1118-22.
15. Sucato V, Novo G, Evola S, Novo S. Coronary microvascular dysfunction in patients with diabetes, hypertension and metabolic syndrome. *Int J Cardiol.* 2015;186:96-7.
16. Padro T, Manfrini O, Bugiardini R, et al. ESC working group on coronary pathophysiology and microcirculation position paper on 'coronary microvascular dysfunction in cardiovascular disease'. *Cardiovasc Res.* 2020;116:741-55.
17. Lane HA, Smith JC, Davies JS. Noninvasive assessment of preclinical atherosclerosis. *Vasc Health Risk Manag.* 2006;2: 19-30.
18. Tondi P, Santoliquido A, Di Giorgio A, et al. Endothelial dysfunction as assessed by flow-mediated dilation in patients with cardiac syndrome X: role of inflammation. *Eur Rev Med Pharmacol Sci.* 2011;15:1074-7.
19. Berwick ZC, Dick GM, Tune JD. Heart of the matter: coronary dysfunction in metabolic syndrome. *J Mol Cell Cardiol* 2012; 52:848-56.

20. Ray SG, McMurray JJ, Morton JJ, Dargie HJ. Circulating endothelin in acute ischaemic syndromes. *Br Heart J*. 1992;67:383-6.
21. Lerman A, Edwards BS, Hallett JW, Heublein DM, Sandberg SM, Burnett JC. Circulating and tissue endothelin immunoreactivity in advanced atherosclerosis. *N Engl J Med*. 1991;325:997-1001.
22. Saito Y, Nakao K, Mukoyama M, Imura H. Increased plasma endothelin level in patients with essential hypertension. *N Engl J Med*. 1990;322:205.
23. Koyama H, Nishizawa Y, Morii H, Tabata T, Inoue T, Yamaji T. Plasma endothelin levels in patients with uraemia. *Lancet*. 1989;1:991-2.
24. Smith TP, Zhang L, Gugino SF, et al. Differential effect of endothelin on coronary conduit and resistance arteries. *Circulation*. 1995;92:1-320.
25. Kaski JC, Elliott PM, Salomone O, et al. Concentration of circulating plasma endothelin in patients with angina and normal coronary angiograms. *Heart*. 1995;74:620-4.
26. Kaski JC, Cox ID, Crook JR, et al. Differential plasma endothelin levels in subgroups of patients with angina and angiographically normal coronary arteries. *Am Heart J*. 1998;136:412-7.
27. Cox ID, Bøtker HE, Bagger JP, Sonne HS, Kristensen BØ, Kaski JC. Elevated endothelin concentrations are associated with reduced coronary vasomotor responses in patients with chest pain and normal coronary arteriograms. *J Am Coll Cardiol*. 1999;34:455-60.
28. Tailor A, Cooper D, Granger DN. Platelet-vessel wall interactions in the microcirculation. *Microcirculation*. 2005;12:275-85.
29. Hamilos M, Petousis S, Parthenakis F. Interaction between platelets and endothelium: from pathophysiology to new therapeutic options. *Cardiovasc Diagn Ther*. 2018;8: 568-80.
30. Muraige C-A, Adam E, Minéo J-F, et al. Endocan expression and localization in human glioblastomas. *J Neuropathol Exp*. 2009;68:633-41.
31. Carrillo LM, Arciniegas E, Rojas H, Ramírez R. Immunolocalization of endocan during the endothelial-mesenchymal transition process. *Eur J Histochem*. 2011;55:e13.
32. Recchia FM, Xu L, Penn JS, Boone B, Dexheimer PJ. Identification of genes and pathways involved in retinal neovascularization by microarray analysis of two animal models of retinal angiogenesis. *Invest Ophthalmol Vis Sci*. 2010;51:1098-105.
33. Balta S, Mikhailidis DP, Demirkol S, Ozturk C, Celik T, Iyisoy A. Endocan: a novel inflammatory indicator in cardiovascular disease? *Atherosclerosis*. 2015;243:339-43.
34. Xiong C, Zhao Z, Chen Z, et al. Elevated human endothelial cell-specific molecule-1 level and its association with coronary artery disease in patients with hypertension. *J Invest Med*. 2015; 63:867-70.
35. Wang X-s, Yang W, Luo T, Wang J, Jing Y. Serum endocan levels are correlated with the presence and severity of coronary artery disease in patients with hypertension. *Genet Test Mol Biomarkers*. 2015;19:124-27.
36. Çimen T, Efe TH, Akyel A, et al. Human endothelial cell-specific molecule-1 (endocan) and coronary artery disease and microvascular angina. *Angiology*. 2016;67:846-53.
37. Efe SC, Demirci K, Ozturk S, et al. Serum endocan levels in patients with cardiac syndrome X. *Herz*. 2017;43:359-63.
38. Eklund L, Kangas J, Saharinen P. Angiopoietin-Tie signalling in the cardiovascular and lymphatic systems. *Clin Sci*. 2017;131:87-103.
39. Chong AY, Caine GJ, Freestone B, Blann AD, Lip GYH. Plasma angiopoietin-1, angiopoietin-2, and angiopoietin receptor tie-2 levels in congestive heart failure. *J Am Coll Cardiol*. 2004;43:423-8.
40. Lee KW, Lip GYH, Blann AD. Plasma angiopoietin-1, angiopoietin-2, angiopoietin receptor tie-2, and vascular endothelial growth factor levels in acute coronary syndromes. *Circulation*. 2004;110:2355-60.
41. Roshani-Asl E, Rasmi Y, Khadem-Ansari M-H, et al. Increased levels of angiogenic factors in microvascular angina. *Med Pharm Rep*. 2019;92:31-5.
42. Asbury EA, Collins P. Cardiac syndrome X. *Int J Clin Pract*. 2005;59:1063-9.
43. Libby P, Ridker PM, Hansson GK. Leducq Transatlantic Network on Atherothrombosis. Inflammation in atherosclerosis: from pathophysiology to practice. *J Am Coll Cardiol*. 2009; 54: 2129-38.
44. Pasceri V, Willerson JT, Yeh ETH. Direct proinflammatory effect of C-reactive protein on human endothelial cells. *Circulation*. 2000;102:2165-8.
45. Willerson JT, Ridker PM. Inflammation as a cardiovascular risk factor. *Circulation*. 2004;109:112-10.
46. Arroyo-Espliguero R, Mollicelli N, Avanzas P, et al. Chronic inflammation and increased arterial stiffness in patients with cardiac syndrome X. *Eur Heart J*. 2003;24:2006-11.
47. Cosin-Sales J, Pizzi C, Brown S, Kaski JC. C-reactive protein, clinical presentation, and ischemic activity in patients with chest pain and normal coronary angiograms. *J Am Coll Cardiol*. 2003; 41:1468-74.
48. Recio-Mayoral A, Rimoldi OE, Camici PG, Kaski JC. Inflammation and microvascular dysfunction in cardiac syndrome X patients without conventional risk factors for coronary artery disease. *JACC Cardiovasc Imaging*. 2013;6:660-7.
49. Rohde LE, Lee RT, Rivero J, et al. Circulating cell adhesion molecules are correlated with ultrasound-based assessment of carotid atherosclerosis. *Arterioscler Thromb Vasc Biol*. 1998; 18:1765-70.
50. Tousoulis D, Daves GJ, Asimakopoulos G, et al. Vascular cell adhesion molecule-1 and intercellular adhesion molecule-1 serum level in patients with chest pain and normal coronary arteries (syndrome X). *Clin Cardiol*. 2001;24:301-4.
51. Shim BJ, Lee DH, Youn HJ. Increased soluble vascular adhesion molecule-1 concentration is associated with impaired coronary flow reserve in cardiac syndrome X. *Heart Ves*. 2014;29:723-31.
52. Liang K-W, Sheu WH-H, Lee W-J, Lee W-L, Fu C-P, Wang J-S. Differential expression of circulating vascular cell adhesion molecule-1 in subjects with coronary artery disease and cardiac syndrome X without known diabetes mellitus. *Biomarkers*. 2017;22:798-804.

53. Ait-Oufella H, Taleb S, Mallat Z, Tedgui A. Recent advances on the role of cytokines in atherosclerosis. *Arterioscler Thromb Vasc Biol.* 2011;31:969-79.
54. Ross R. Atherosclerosis-an inflammatory disease. *N Engl J Med.* 1999;340:115-26.
55. Deo R, Khera A, McGuire DK, et al. Association among plasma levels of monocyte chemoattractant protein-1, traditional cardiovascular risk factors, and subclinical atherosclerosis. *J Am Coll Cardiol.* 2004;44:1812-18.
56. On YK, Park R, Hyon MS, Kim SK, Kwon YJ. Are low total serum antioxidant status and elevated levels of C-reactive protein and monocyte chemotactic protein-1 associated with cardiac syndrome X? *Circ J.* 2005;69:1212-7.
57. Li J-J, Zhu C-G, Nan J-L, et al. Elevated circulating inflammatory markers in female patients with cardiac syndrome X. *Cytokine.* 2007;40:172-76.
58. Aslan G, Polat V, Bozcali E, Opan S, Çetin N, Ural D. Evaluation of serum sST2 and sCD40L values in patients with microvascular angina. *Microvasc Res.* 2019;122:85-93.
59. Schroder J, Mygind ND, Frestad D, et al. Pro-inflammatory biomarkers in women with non-obstructive angina pectoris and coronary microvascular dysfunction. *Int J Cardiol Heart Vasc.* 2019;24:100370.
60. Canpolat U, Çetin EH, Cetin S, et al. Association of monocyte-to-HDL cholesterol ratio with slow coronary flow is linked to systemic inflammation. *Clin Appl Thromb Hemost.* 2016;22:476-82.
61. Kanbay M, Solak Y, Unal HU, et al. Monocyte count/HDL cholesterol ratio and cardiovascular events in patients with chronic kidney disease. *Int Urol Nephrol.* 2014;46:1619-25.
62. Dogan A, Oylumlu M. Increased monocyte-to-HDL cholesterol ratio is related to cardiac syndrome X. *Acta Cardiol.* 2017;72:516-21.
63. Brown DW, Giles WH, Croft JB. White blood cell count: an independent predictor of coronary heart disease mortality among a national cohort. *J Clin Epidemiol.* 2001;54:316-22.
64. Dubin R, Li Y, Ix JH, Shlipak MG, Whooley M, Peralta CA. Associations of pentraxin-3 with cardiovascular events, incident heart failure, and mortality among persons with coronary heart disease: data from the heart and soul study. *Am Heart J.* 2012;163:274-9.
65. Büyükkaya E, Karakas MF, Kurt M, et al. The serum pentraxin-3 is elevated in patients with cardiac syndrome X. *Türk Kardiyol Dern Ars.* 2013;41:290-95.
66. Thunø M, Macho B, Eugen-Olsen J. suPAR: the molecular crystal ball. *Dis Markers.* 2009;27:157-72.
67. Eapen DJ, Manocha P, Ghasemzadeh N, et al. Soluble urokinase plasminogen activator receptor level is an independent predictor of the presence and severity of coronary artery disease and of future adverse events. *J Am Heart Assoc.* 2014;3:e001118.
68. Lyngbaek S, Andersson C, Marott JL, et al. Soluble urokinase plasminogen activator receptor for risk prediction in patients admitted with acute chest pain. *Clin Chem.* 2013;59:1621-29.
69. Mekonnen G, Corban MT, Hung OY, et al. Plasma soluble urokinase-type plasminogen activator receptor level is independently associated with coronary microvascular function in patients with non-obstructive coronary artery disease. *Atherosclerosis.* 2015;239:55-60.
70. Corban MT, Prasad A, Nesbitt L, et al. Local production of soluble urokinase plasminogen activator receptor and plasminogen activator inhibitor-1 in the coronary circulation is associated with coronary endothelial dysfunction in humans. *J Am Heart Assoc.* 2018;7:e009881.
71. Xu Q. Role of heat shock proteins in atherosclerosis. *Arterioscler Thromb Vasc Biol.* 2002;22:1547-59.
72. Dybdahl B, Slordahl SA, Waage A, et al. Myocardial ischaemia and the inflammatory response: release of heat shock protein 70 after myocardial infarction. *Heart.* 2005;91:299-304.
73. Giannesi D, Colotti C, Maltinti M, et al. Circulating heat shock proteins and inflammatory markers in patients with idiopathic left ventricular dysfunction: their relationships with myocardial and microvascular impairment. *Cell Stress Chaperones.* 2007;12:265-74.
74. Vogel RA. Coronary risk factors, endothelial function, and atherosclerosis: a review. *Clin Cardiol.* 1997;20:426-32.
75. Harrison DG, Ohara Y. Physiologic consequences of increased vascular oxidant stresses in hypercholesterolemia and atherosclerosis: implications for impaired vasomotion. *Am J Cardiol.* 1995;75:75B-81B.
76. Ikeda U, Takahashi M, Shimada K. Monocyte-endothelial cell interaction in atherogenesis and thrombosis. *Clin Cardiol.* 1998;21:11-4.
77. Egashira K, Inou T, Hirooka Y, Yamada A, Urabe Y, Takeshita A. Evidence of impaired endothelium-dependent coronary vasodilatation in patients with angina pectoris and normal coronary angiograms. *N Engl J Med.* 1993;328:1659-64.
78. Joannides R, Haefeli WE, Linder L, et al. Nitric oxide is responsible for flow-dependent dilatation of human peripheral conduit arteries in vivo. *Circulation.* 1995;91:1314-9.
79. Ionescu JG, Merk M, Bradford R. Redox and free radical monitoring in the clinical practice. *J Integrative Med.* 1999;1:73-5.
80. Davies B, Edwards SW. Chemiluminescence of human bloodstream monocytes and neutrophils: an unusual oxidant(s) generated by monocytes during the respiratory burst. *J Biolumin Chemilumin.* 1992;7:229-38.
81. Lin C-P, Lin W-T, Leu H-B, Wu T-C, Chen J-W. Differential mononuclear cell activity and endothelial inflammation in coronary artery disease and cardiac syndrome X. *Int J Cardiol.* 2003;89:53-62.
82. Moncada S, Palmer RM, Higgs EA. Nitric oxide: physiology, pathophysiology, and pharmacology. *Pharmacol Rev.* 1991;43:109-42.
83. Radomski MW, Palmer RMJ, Moncada S. Endogenous nitric oxide inhibits human platelet adhesion to vascular endothelium. *Lancet.* 1987;2:1057-8.
84. Caplin B, Leiper J. Endogenous nitric oxide synthase inhibitors in the biology of disease: markers, mediators, and regulators? *Arterioscler Thromb Vasc Biol.* 2012;32:1343-53.
85. Böger RH, Bode-Böger SM, Szuba A, et al. Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia. *Circulation.* 1998;98:1842-7.

86. Perticone F, Sciacqua A, Maio R, et al. Asymmetric dimethylarginine, L-arginine, and endothelial dysfunction in essential hypertension. *J Am Coll Cardiol*. 2005;46:518-23.
87. Wood KC, Cortese-Krott MM, Kovacic JC, et al. Circulating blood endothelial nitric oxide synthase contributes to the regulation of systemic blood pressure and nitrite homeostasis. *Arterioscler Thromb Vasc Biol*. 2013; 33:1861-71.
88. Yang J, Gonon AT, Sjöquist P-O, Lundberg JO, Pernow J. Arginase regulates red blood cell nitric oxide synthase and export of cardioprotective nitric oxide bioactivity. *Proc Natl Acad Sci Unit States Am*. 2013;110:15049-54.
89. Heiss C, Lauer T, Dejam A, et al. Plasma nitroso compounds are decreased in patients with endothelial dysfunction. *J Am Coll Cardiol*. 2006;47:573-79.
90. Okyay K, Cengel A, Sahinarslan A, et al. Plasma asymmetric dimethylarginine and L-arginine levels in patients with cardiac syndrome X. *Coron Artery Dis*. 2007;18:539-44.
91. Sen N, Poyraz F, Tavil Y, et al. Carotid intima-media thickness in patients with cardiac syndrome X and its association with high circulating levels of asymmetric dimethylarginine. *Atherosclerosis*. 2009;204:e82-5.
92. Porro B, Eligini S, Veglia F, et al. Nitric oxide synthetic pathway in patients with microvascular angina and its relations with oxidative stress. *Oxid Med Cell Longev*. 2014;2014:726539.
93. Ashfaq S, Abramson JL, Jones DP, et al. Endothelial function and aminothiols biomarkers of oxidative stress in healthy adults. *Hypertension*. 2008;52:80-5.
94. Erel O, Neselioglu S. A novel and automated assay for thiol/disulphide homeostasis. *Clin Biochem*. 2014;47:326-32.
95. Dhawan SS, Eshtehardi P, McDaniel MC, et al. The role of plasma aminothiols in the prediction of coronary microvascular dysfunction and plaque vulnerability. *Atherosclerosis*. 2011; 219:266-72.
96. Tsimikas S, Willerson JT, Ridker PM. C-reactive protein and other emerging blood biomarkers to optimize risk stratification of vulnerable patients. *J Am Coll Cardiol*. 2006;47:C19-31.
97. Kaufmann PA, Gnechi-Ruscone T, Schäfers KP, Lüscher TF, Camici PG. Low density lipoprotein cholesterol and coronary microvascular dysfunction in hypercholesterolemia. *J Am Coll Cardiol*. 2000;36:103-9.
98. Mangiacapra F, De Bruyne B, Peace AJ, Melikian N, Wijns W, Barbato E. High cholesterol levels are associated with coronary microvascular dysfunction. *J Cardiovasc Med*. 2012;13:439-42.
99. Canales A, Sánchez-Muniz FJ. Paraoxonase, something more than an enzyme? *Med Clínica*. 2003;121:537-48.
100. Aviram M, Rosenblat M. Paraoxonase 1, 2, and 3, oxidative stress, and macrophage foam cell formation during atherosclerosis development. *Free Radic Biol Med*. 2004;37:1304-16.
101. Gur M, Yildiz A, Demirbag R, et al. Paraoxonase and arylesterase activities in patients with cardiac syndrome X, and their relationship with oxidative stress markers. *Coron Artery Dis*. 2007;18:89-95.
102. Halliwell B, Aruoma OI. DNA damage by oxygen-derived species: its mechanism and measurement in mammalian systems. *FEBS Lett*. 1991;281:9-19.
103. Botto N, Masetti S, Petrozzi L, et al. Elevated levels of oxidative DNA damage in patients with coronary artery disease. *Coron Artery Dis*. 2002;13:269-74.
104. Gur M, Yildiz A, Demirbag R, et al. Increased lymphocyte deoxyribonucleic acid damage in patients with cardiac syndrome X. *Mutat Res*. 2007;617:8-15.
105. Tomiyama H, Kimura Y, Mitsuhashi H, et al. Relationship between endothelial function and fibrinolysis in early hypertension. *Hypertension*. 1998;31:321-27.
106. Ouchi N, Kihara S, Arita Y, et al. Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. *Circulation*. 1999;100:2473-76.
107. Sawabe M, Tanaka N, Nakahara K, et al. High lipoprotein(a) level promotes both coronary atherosclerosis and myocardial infarction: a path analysis using a large number of autopsy cases. *Heart*. 2009;95:1997-2002.
108. Bozcali E, Polat V, Aciksari G, et al. Serum concentrations of galectin-3 in patients with cardiac syndrome X. *Atherosclerosis*. 2014;237:259-63.
109. Hill JM, Zalos G, Halcox JPI, et al. Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. *N Engl J Med*. 2003;348:593-600.
110. Sucato V, Evola S, Novo G, et al. The association between coronary microvascular dysfunction and carotid intima media thickness in patients with cardiac syndrome X. *Int J Cardiol*. 2016;214:383-6.
111. Novo G, Manno G, Russo R, et al. Impact of insulin resistance on cardiac and vascular function. *Int J Cardiol*. 2016;221:1095-9.
112. Sucato V, Novo G, Saladino A, et al. Ischemia in patients with no obstructive coronary artery disease: classification, diagnosis and treatment of coronary microvascular dysfunction. *Coron Artery Dis*. 2020;31:472-6.
113. Sucato V, Novo S, Rubino M, D'Agostino A, Evola S, Novo G. Prognosis in patients with microvascular angina: a clinical follow-up. *J Cardiovasc Med*. 2019;20:794-5.
114. Sucato V, Evola S, Quagliana A, et al. Comparison of coronary artery flow impairment in diabetic and hypertensive patients with stable microvascular angina. *Eur Rev Med Pharmacol Sci*. 2014;18:3687-9.
115. Clarke JG, Kerwin R, Larkin S, et al. Coronary artery infusion of neuropeptide Y in patients with angina pectoris. *Lancet*. 1987;1: 1057-9.
116. Sucato V, Galassi AR, Novo S, Saladino A, Evola S, Novo G. Correlation between longitudinal strain analysis and coronary microvascular dysfunction in patients with heart failure with preserved ejection fraction. *Microcirculation*. 2020;27:e12605.
117. Montone RA, Vetrugno V, Santacroce G, Del Buono MG, Meucci MC, Camilli M, et al. Recurrence of angina after ST-segment elevation myocardial infarction: the role of coronary microvascular obstruction. *Eur Heart J Acute Cardiovasc Care*. 2019;16:2048872619880661.

Copyright of Angiology is the property of Sage Publications Inc. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use.